AYTU BioPharma, Inc. Common Stock (AYTU) Stock Price

AYTUStock

$2.35+2.40%52W

Market Cap$25.22M

P/E—

PEG Ratio—

Div yield—

Beta0.15

AYTU Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-10.16%

Price vs S&P 500 (4W)7.98%

VGM Score58.13

Book Value / Share (Quarterly)$3.27

P/TBV (Annual)2.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-11.79%

Cash Flow / Share (Quarterly)$-0.13

Price vs S&P 500 (YTD)-21.93%

Gross Margin (TTM)64.78%

Net Profit Margin (TTM)-60.17%

EPS (TTM)$-4.41

10-Day Avg Trading Volume0.03M

EPS Excl Extra (TTM)$-4.41

Revenue Growth (5Y)19.19%

EPS (Annual)$-2.16

ROI (Annual)-33.26%

Gross Margin (Annual)69.04%

Net Profit Margin (5Y Avg)-51.46%

Cash / Share (Quarterly)$2.49

Revenue Growth QoQ (YoY)-32.74%

ROA (Last FY)-10.92%

Revenue Growth TTM (YoY)-18.24%

EBITD / Share (TTM)$-1.07

ROE (5Y Avg)-90.09%

Operating Margin (TTM)-26.79%

Cash Flow / Share (Annual)$-0.58

P/B Ratio0.72x

P/B Ratio (Quarterly)0.83x

Net Income / Employee (Annual)$-165,400

EV / Revenue (TTM)0.36x

Net Interest Coverage (TTM)-1.32x

ROA (TTM)-28.21%

EV / EBITDA (TTM)5.58x

EPS Incl Extra (Annual)$-2.16

Current Ratio (Annual)1.26x

Quick Ratio (Quarterly)0.85x

3-Month Avg Trading Volume0.03M

52-Week Price Return2.40%

Revenue / Employee (TTM)$690,200

Tangible BV / Share (Quarterly)$16.13

P/S Ratio (Annual)0.38x

Asset Turnover (Annual)0.53x

52-Week High$3.06

Operating Margin (5Y Avg)-47.18%

EPS Excl Extra (Annual)$-2.16

26-Week Price Return1.73%

Quick Ratio (Annual)0.98x

13-Week Price Return7.31%

Total Debt / Equity (Annual)1.15x

Current Ratio (Quarterly)1.12x

Enterprise Value$20.54M

Revenue / Share Growth (5Y)-40.18%

Asset Turnover (TTM)0.47x

Book Value / Share Growth (5Y)-57.82%

Revenue / Employee (Annual)$809,500

Inventory Turnover (Annual)1.71x

Pretax Margin (Annual)-20.71%

Cash / Share (Annual)$3.45

3-Month Return Std Dev42.45%

Gross Margin (5Y Avg)58.04%

Net Income / Employee (TTM)$-415,300

ROE (Last FY)-71.51%

Net Interest Coverage (Annual)-0.62x

EPS Basic Excl Extra (Annual)$-2.16

P/FCF (TTM)3.66x

Receivables Turnover (TTM)1.88x

Total Debt / Equity (Quarterly)0.62x

EPS Incl Extra (TTM)$-4.41

Receivables Turnover (Annual)2.42x

ROI (TTM)-74.35%

P/S Ratio (TTM)0.45x

Pretax Margin (5Y Avg)-50.09%

Revenue / Share (Annual)$10.57

Tangible BV / Share (Annual)$37.21

Price vs S&P 500 (52W)-16.82%

Year-to-Date Return-9.62%

5-Day Price Return-0.42%

EPS Normalized (Annual)$-2.16

ROA (5Y Avg)-27.58%

Net Profit Margin (Annual)-20.43%

Month-to-Date Return5.38%

Cash Flow / Share (TTM)$-3.85

EBITD / Share (Annual)$-0.66

Operating Margin (Annual)-11.79%

LT Debt / Equity (Annual)0.57x

P/CF (TTM)15.16x

ROI (5Y Avg)-61.20%

LT Debt / Equity (Quarterly)0.27x

EPS Basic Excl Extra (TTM)$-4.41

P/TBV (Quarterly)1.67x

P/B Ratio (Annual)1.03x

Inventory Turnover (TTM)2.15x

Pretax Margin (TTM)-59.49%

Book Value / Share (Annual)$2.11

Price vs S&P 500 (13W)4.59%

Beta0.15x

Revenue / Share (TTM)$5.38

ROE (TTM)-148.91%

52-Week Low$1.65

vGradeA

gGradeD

mGradeC

vgmGradeC

AYTU Earnings Surprise History

Q2 25-0.08est. -0.06

Q3 25-0.09est. -0.20

Q4 25-0.23est. -0.49

Q1 26-0.41est. -0.42

AYTU Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
AYTUAYTU BioPharma, Inc. Common Stock	A	D	C	$2.35
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About AYTU BioPharma, Inc. Common Stock

Aytu BioPharma is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products, focusing on pediatric conditions including ADHD. The company is building a clinical pipeline that includes a prospective treatment for vascular Ehlers-Danlos Syndrome, a rare genetic disorder associated with significant morbidity.